TITLE

Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer

AUTHOR(S)
Jover, R.; Zapater, P.; Castells, A.; Llor, X.; Andreu, M.; Cubiella, J.; Piñol, V.; Xicola, R. M.; Bujanda, L.; Reñé, J. M.; Clofent, J.; Bessa, X.; Morillas, J. D.; Nicolás-Pérez, D.; Payá, A.; Alenda, C.
PUB. DATE
June 2006
SOURCE
Gut;Jun2006, Vol. 55 Issue 6, p848
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Aim: Some retrospective studies have shown a lack of benefit of 5-fluorouracil (5-FU) adjuvant chemotherapy in patients with mismatch repair (MMR) deficient colorectal cancer. Our aim was to assess if this molecular marker can predict benefit from 5-FU adjuvant chemotherapy. A second objective was to determine if MMR status influences short term survival. Methods: We included 754 patients with a median follow up of 728.5 days (range 1-1097). A total of 260 patients with stage II or III tumours received 5-FU adjuvant chemotherapy, according to standard clinical criteria and irrespective of their MMR status. A tumour was considered MMR deficient when either BAT-26 showed instability or there was loss of MLH1 or MSH2 protein expression. Results: At the end of the follow up period, 206 patients died and 120 presented with tumour recurrence. Sixty six (8.8%) patients had MMR deficient tumours. There were no significant differences in overall survival (MMR competent 72.1%; MMR deficient 78.8%; p = 0.3) or disease free survival (MMR competent 61.3%; MMR deficient 72.3%; p=0.08). In patients with stage II and III tumours, benefit from 5-FU adjuvant chemotherapy was restricted to patients with MMR competent tumours (overall survival: chemotherapy 87.1%; non-chemotherapy 73.5%; log rank, p=0.00001). Patients with MMR deficient tumours did not benefit from adjuvant chemotherapy (overall survival: chemotherapy 89.5%; non-chemotherapy 82.4%; log rank, p=0.4). Conclusions: Benefit from 5-FU adjuvant chemotherapy depends on the MMR status of tumours in patients with colorectal cancer. 5-FU adjuvant chemotherapy improves survival in patients with MMR competent tumours but this benefit from chemotherapy cannot be extended to patients with MMR deficient tumours.
ACCESSION #
22212752

 

Related Articles

  • Adjuvant perioperative portal vein or peripheral intravenous chemotherapy for potentially curative colorectal cancer: long-term results of a randomized controlled trial. Laffer, U.; Metzger, U.; Aeberhard, P.; Lorenz, M.; Harder, F.; Maibach, R.; Zuber, M.; Herrmann, R. // International Journal of Colorectal Disease;Dec2008, Vol. 23 Issue 12, p1233 

    The perioperative use of a single course adjuvant portal vein infusion chemotherapy in patients with potentially curable colorectal cancer has been shown to significantly improve overall survival but did not reduce the occurrence of liver metastases (SAKK 40/81) [Swiss Group for Clinical Cancer...

  • Diffusion-weighted MR imaging of Carmofur-induced leukoencephalopathy. Fujikawa, Akira; Tsuchiya, Kazuhiro; Katase, Shichiro; Kurosaki, Yoshihisa; Hachiya, Junichi // European Radiology;Dec2001, Vol. 11 Issue 12, p2602 

    Carmofur (1-hexylcarbamyl-5-fluorouracil), a derivative of 5-fluorouracil (5-FU), has been widely used in Japan as a postoperative adjuvant chemotherapy agent for colorectal and breast cancer. Periventricular hyperintensity on T2-weighted MR images in carmofur-induced leukoencephalopathy...

  • The Colorectal Cancer Coalition: Reflections on the Future. JOHNSTON, PATRICK G. // Oncologist;Oct2006, Vol. 11 Issue 9, p970 

    The article talks about the formation of an international Colorectal Cancer Coalition (CCC) to openly address important issues on colorectal cancer. It presents a summary of the key points of discussion during the inaugural convocation of the CCC. Benefits of adjuvant therapy, impact of novel...

  • Chemotherapy of Breast Cancer in the Elderly. Rossi, A.; Colantuoni, G.; Maione, P.; Ferrara, C.; Airoma, G.; Barzelloni, M. L.; Castaldo, V.; Gridelli, C. // Current Medicinal Chemistry;2005, Vol. 12 Issue 3, p297 

    Breast cancer arises in about 48% of patients older than 65 years and more than 30% occurs in those over 70 years being the leading cause of cancer-related death in women older than 65. Elderly patients tolerate chemotherapy poorly compared to their younger counterpart because of progressive...

  • Effect of Gender on Coagulation Functions: A Study in Metastatic Colorectal Cancer Patients Treated with Bevacizumab, Irinotecan, 5-Fluorouracil, and Leucovorin. Bilir, Cemil; Engin, Hüseyin; Temi, Yasemin Bakkal // Advances in Hematology;2014, p1 

    Introduction. We designed this study to evaluate how coagulation parameters are changed in metastatic colorectal cancer (mCRC) patients treated with bevacizumab, irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI). Methods. A total of 48 mCRC patients who initially received bevacizumab with...

  • In this issue.  // Annals of Oncology;Aug2010, Vol. 21 Issue 8, p1567 

    The article discusses various reports published within the issue, including one on results of trial of adjuvant 5-FU infusional chemotherapy and another on results of a study that intended to examine protein expression of AIB1.

  • Adjuvant chemotherapy for colorectal cancer. Maughan, T S // British Journal of Cancer;11/15/2001, Vol. 85 Issue 10, p1422 

    Editorial. Discusses the role of adjuvant chemotherapy in colorectal cancer patients. Effect of the chemotherapy on node-negative patients; Duration of chemotherapy; Identification of poor prognostic factors.

  • A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Schippinger, W.; Samonigg, H.; Schaberl-Moser, R.; Greil, R.; Thödtmann, R.; Tschmelitsch, J.; Jagoditsch, M.; Steger, G. G.; Jakesz, R.; Herbst, F.; Hofbauer, F.; Rabl, H.; Wohlmuth, P.; Gnant, M.; Thaler, J. // British Journal of Cancer;10/22/2007, Vol. 97 Issue 8, p1021 

    The purpose of this trial was to investigate the efficacy of adjuvant chemotherapy with 5-fluorouracil (5-FU) and leucovorin (LV) in stage II colon cancer. Patients with stage II colon cancer were randomised to either adjuvant chemotherapy with 5-FU/LV (100 mg m−2 LV+450 mg m−2 5-FU...

  • Expanded Treatment Options in the Adjuvant Therapy of Colon Cancer: Implications for Oncology Nurses. Hallquist, Pamela // Oncology Nursing Forum;Jan2006, Vol. 33 Issue 1, p81 

    Purpose/Objectives: To review the role of adjuvant therapy in the treatment of patients with colon cancer. Data Sources: Published articles, Internet sources, and books. Data Synthesis: Colon cancer is a very common cancer in men and women. Chemotherapy, consisting primarily of 5-fluorouracil,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics